Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06016465 · ClinicalTrials.gov registry record · Early Phase 1
Does Nerve Block + Oral Dexamethasone Reduce Recurrence of Headache Within 72 Hrs?
A Early Phase 1 study of Migraine, sponsored by Texas Tech University Health Sciences Center, El Paso.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 84
- Enrollment target
- 1
- Study location
NCT06016465: Recruiting Early Phase 1 study of Migraine, sponsored by Texas Tech University Health Sciences Center, El Paso.
NCT06016465 is a Early Phase 1 study of Migraine that is actively recruiting participants, run by Texas Tech University Health Sciences Center, El Paso. The registered enrollment target is 84 participants, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06016465, a Early Phase 1 study of Migraine, is actively recruiting participants, sponsored by Texas Tech University Health Sciences Center, El Paso.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
For some patients who come to the emergency department for treatment of a migraine headache, peripheral headache nerve blocks (PHNB) have proven to be an efficient and effective treatment for headache relief. Previous studies have demonstrated that adding steroids as an adjunct treatment to standard migraine treatment can reduce recurrence of headaches in the subsequent few days.
Primary Outcome
Subjects will be contacted 72 hrs post treatment to determine if migraine headache has recurred
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dexamethasone Oral
Study Locations (1)
Texas
- University Medical Center of El Paso - El Paso
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2023-09-15 |
| Est. Completion | 2026-01-30 |
| Phase | Early Phase 1 |
What NCT06016465 shows while recruiting
NCT06016465 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06016465 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06016465 about?
NCT06016465 is a clinical study titled "Does Nerve Block + Oral Dexamethasone Reduce Recurrence of Headache Within 72 Hrs?". For some patients who come to the emergency department for treatment of a migraine headache, peripheral headache nerve blocks (PHNB) have proven to be an efficient and effective treatment for headache relief. Previous studies have demonstrated that adding steroids as an adjunct treatment to standard...
What is the current status of trial NCT06016465?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 84 participants. The study started on 2023-09-15. Estimated completion is 2026-01-30.
What conditions does trial NCT06016465 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT06016465?
The interventions under investigation include: Placebo (DRUG), Dexamethasone Oral (DRUG).
Who is sponsoring clinical trial NCT06016465?
This trial is sponsored by Texas Tech University Health Sciences Center, El Paso, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06016465 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06016465's enrollment target sits among peer trials
84 64th of 102 higher than 38 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mechanistic Studies of Psilocybin in Headache Disorders
RECRUITING · Early Phase 1
-
Migraine Manager (R01)
RECRUITING · Phase 2
-
MMA Embolization for Refractory Chronic Migraine
RECRUITING · NA
-
Stimulation of External Carotid Artery Circulation
RECRUITING · NA
-
Efficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents
RECRUITING
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI